New Insights in the Management of Hepatocellular Adenoma

Anne J. Klompenhouwer; Robert A. de Man; Marco Dioguardi Burgio; Valerie Vilgrain; Jessica Zucman-Rossi; Jan N. M. Ijzermans


Liver International. 2020;40(7):1529-1537. 

In This Article

Final Remarks

HCA may be considered a rare disease. The small number of patients and the limited epidemiological data pose challenges for research and the clinical development. It is preferable to treat patients with suspected HCA in high volume centres with combined expertise of liver surgeons, hepatologists, radiologists and (molecular) pathologists. To optimize the validity and reliability of future research, it is important to collaborate in (inter)national multicentre consortia to optimize our insights in diagnosis and treatment of this rare disease.